Table 1 Baseline characteristics stratified by EGFR gene status in advanced NSCLC
Characteristics | Total (n = 91) | EGFR negative (n = 60) | EGFR mutation (n = 31) |
|---|---|---|---|
Age | |||
Median (range) | 69 (65–84) | 69 (65–84) | 68 (65–77) |
Sex | |||
Male | 68 (74.7%) | 53 (88.3%) | 15 (48.4%) |
Female | 23 (25.3%) | 7 (11.7%) | 16 (51.6%) |
Smoking history | |||
Never smoking | 27 (29.7%) | 9 (15.0%) | 18 (58.1%) |
Ever smoking | 64 (70.3%) | 57 (85.0%) | 13 (41.9%) |
ECOG PS | |||
0–1 | 84 (92.3%) | 57 (95.0%) | 27 (87.1%) |
2 | 7 (7.7%) | 3 (5.0%) | 4 (12.9%) |
Histological | |||
Adenocarcinoma | 50 (54.9%) | 21 (35.0%) | 29 (93.5%) |
Others | 41 (45.1%) | 39 (65.0%) | 2 (6.5%) |
Liver metastases | |||
No | 80 (87.9%) | 51 (85.0%) | 29 (93.5%) |
Yes | 11 (12.1%) | 9 (15.0%) | 2 (6.5%) |
Brain metastases | |||
No | 83 (91.2%) | 56 (93.3%) | 27 (87.1%) |
Yes | 8 (8.8%) | 4 (6.7%) | 4 (12.9%) |
KRAS gene status | |||
Mutation | 5 (5.5%) | 5 (8.3%) | 0 |
Negative | 24 (26.4) | 14 (23.3%) | 10 (32.3%) |
Unknown | 62 (68.1%) | 41 (68.4%) | 21 (67.7%) |
Anlotinib treatment modes | |||
Monotherapy | 56 (61.5%) | 38 (63.3%) | 18 (58.1%) |
Combination | 35 (38.5%) | 22 (36.7%) | 13 (41.9%) |
Lines of Anlotinib treatment | |||
First-line | 9 (9.9%) | 8 (13.3%) | 1 (3.2%) |
≥ Second-line | 82 (90.1%) | 52 (86.7%) | 30 (86.8%) |